Sugi Predict

Sugi Predict / Targets / CACNB1

CACNB1

Voltage-dependent L-type calcium channel subu · Q02641 · CACNB1 on Sugi Atlas →

15,661 patent compounds predicted against CACNB1, 7,582 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL770523 SCHEMBL770523 0.54 12/20
SCHEMBL1798984 SCHEMBL1798984 0.53 12/20
SCHEMBL1799860 SCHEMBL1799860 0.53 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1800586) 0.52 12/20
SCHEMBL1796175 SCHEMBL1796175 0.51 12/20
SCHEMBL1798627 SCHEMBL1798627 0.51 12/20
SCHEMBL1799473 SCHEMBL1799473 0.51 12/20
SCHEMBL1799855 SCHEMBL1799855 0.51 12/20
SCHEMBL1797968 SCHEMBL1797968 0.48 12/20
SCHEMBL1797970 SCHEMBL1797970 0.48 12/20
SCHEMBL1798505 SCHEMBL1798505 0.53 11/20
SCHEMBL1796173 SCHEMBL1796173 0.51 11/20
SCHEMBL1798810 SCHEMBL1798810 0.51 11/20
SCHEMBL1797251 SCHEMBL1797251 0.49 11/20
SCHEMBL1800427 SCHEMBL1800427 0.48 11/20
SCHEMBL1799425 SCHEMBL1799425 0.47 11/20
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL1795515 SCHEMBL1795515 0.44 11/20
SCHEMBL1795630 SCHEMBL1795630 0.42 11/20
SCHEMBL1799443 SCHEMBL1799443 0.41 11/20

Clinical trials — most relevant to CACNB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain PHASE4RECRUITING
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis PHASE2COMPLETED
Calcium Channel Blockade in Primary Aldosteronism PHASE2COMPLETED
International CRDS Registry nanRECRUITING
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Verapamil in Supraclavicular Brachial Plexus Block nanUNKNOWN
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia nanCOMPLETED
A Natural History Study of RYR1-Related Disorders nanRECRUITING
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING
MRI-phenotyping of Patients With Pathogenic Anoctamin 5 Variants nanRECRUITING
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
iCorMicA - Stratified Medicine in Angina nanRECRUITING
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism nanCOMPLETED
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
Pharmacogenetics and Cardiovascular Events nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNB1 binder may also engage these)

ProteinNameSimilarity
Q9MZL7 — 1.000 Q9MZL7 →
Q8R3Z5 — 1.000 Q8R3Z5 →
P54283 — 1.000 P54283 →
Q8VGC3 — 0.997 Q8VGC3 →
Q8CC27 — 0.996 Q8CC27 →
P54286 — 0.993 P54286 →
P54287 — 0.990 P54287 →
CACNB3 Voltage-dependent L-type calcium channel subunit beta-3 0.988 landscape →
Q9MZL3 — 0.988 Q9MZL3 →
P54285 — 0.985 P54285 →
CACNB2 Voltage-dependent L-type calcium channel subunit beta-2 0.984 landscape →
Q9MZL5 — 0.984 Q9MZL5 →
P19517 — 0.983 P19517 →
P54288 — 0.982 P54288 →
Q9BTC8 — 0.967 Q9BTC8 →
O95049 — 0.967 O95049 →
Q9UQB3 — 0.966 Q9UQB3 →
Q5PYH7 — 0.965 Q5PYH7 →
Q924K8 — 0.964 Q924K8 →
Q6P9S0 — 0.964 Q6P9S0 →
Q923Q2 — 0.963 Q923Q2 →
O94776 — 0.963 O94776 →
F1QWK4 — 0.962 F1QWK4 →
Q61062 — 0.962 Q61062 →
O62683 — 0.962 O62683 →
O60784 — 0.962 O60784 →
Q9Z1N9 — 0.962 Q9Z1N9 →
Q9R0Z9 — 0.962 Q9R0Z9 →
A6QL72 — 0.962 A6QL72 →
Q95168 — 0.961 Q95168 →